Upper-airway stimulation for obstructive sleep apnea.
Level 2 - randomized trial
Prospective cohort study with an embedded randomized controlled therapy-withdrawal trial
PubMed 24401051 · doi:10.1056/NEJMoa1308659
What was done
Investigators evaluated the safety and efficacy of a surgically implanted upper-airway stimulation device in 126 patients with moderate-to-severe obstructive sleep apnea (OSA) who were intolerant of or non-adherent to CPAP. In a multicenter prospective single-arm study, patients were followed for 12 months. Primary outcomes were the apnea-hypopnea index (AHI) and oxygen desaturation index (ODI). Secondary outcomes included daytime sleepiness (Epworth Sleepiness Scale), quality of life (FOSQ), and sleep time with oxygen saturation below 90%. To confirm device efficacy, a randomized controlled therapy-withdrawal study was conducted in a subset of consecutive responders (23 maintained on therapy, 23 randomized to withdrawal).
What was found
Among 126 participants (83% men, mean age 54.5 years, mean BMI 28.4 kg/m²), the median AHI at 12 months decreased 68% from 29.3 to 9.0 events per hour (P < 0.001), and the median ODI decreased 70% from 25.4 to 7.4 events per hour (P < 0.001). Secondary measures of sleepiness and quality of life also improved. In the randomized withdrawal phase, mean AHI remained low in the therapy-maintenance group (8.9 vs. 7.2 events per hour, non-significant change), but increased markedly in the therapy-withdrawal group (25.8 vs. 7.6 events per hour, P < 0.001). ODI showed a similar recurrence of desaturations upon withdrawal. Procedure-related serious adverse events occurred in less than 2% of patients.
Why it matters
Upper-airway stimulation provides an effective surgical alternative for moderate-to-severe OSA patients who cannot tolerate CPAP. The randomized withdrawal design confirmed that symptom improvements were directly attributable to active electrical stimulation rather than placebo effects or baseline regression.
Limits
The main 12-month study lacked an upfront parallel control or sham-surgery group. The study population was predominantly male (83%) with a relatively modest average BMI (28.4 kg/m²), which may limit generalizability to more severely obese populations. The randomized withdrawal trial was restricted to a subset of responders (n = 46) and assessed short-term withdrawal rather than long-term durability.
Cited by
- supports Implantable hypoglossal nerve stimulation devices (such as Inspire) electrically stimulate upper airway muscles when airway obstruction is detected to maintain airway patency during sleep.